Last reviewed · How we verify
NCT06344338: tDCS
Application of tDCS Stimulation in Controlling Refractory Status Epilepticus
NA trial testing tDCS stimulation in Refractory Status Epilepticus in 32 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 April 2024 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- tDCS stimulation
- TDCS sham-stimulation
Conditions studied
- Refractory Status Epilepticus — all drugs for Refractory Status Epilepticus →
Sponsor
Xuanwu Hospital, Beijing
Who can join
Adults 14 to 80, any sex, with Refractory Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06344338
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tDCS stimulation
Trials testing the same drug.
- NCT06244914 — Combined taVNS and tDCS in Subacute Stroke Patients · NA · recruiting
- NCT07290686 — Evaluation of the Effectiveness and Safety of Transcranial Direct Current Stimulation in Combination With Nasal Near Inf · NA · completed
- NCT03049969 — Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS) · NA · terminated
- NCT05471570 — Effect of Anodal Transcranial Direct Current Stimulation (tDCS) Over the Right-hemisphere on Picture Naming in Chronic A · NA · completed
Other recruiting trials for Refractory Status Epilepticus
Currently open trials in the same condition.
- NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06344338 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 31 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06344338.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing